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Effect of atrial natriuretic factor on renin release in isolated afferent
arterioles. This study was designed to examine the effect of a-human
atrial natriuretic polypeptide (a-hANP) on renin release in the absence
of tubules, glomeruli and macula densa. Rabbit afferent arterioles were
microdissected and incubated for two consecutive, 20 minute periods.
Hourly renin release rate from a single arteriole was calculated. Basal
renin release rate was 0.97 0.13 ng Al . hr' Af'/hr (x SEM, N =
18) and remained stable throughout the incubations. When afferent
arterioles were exposed to a-hANP (0.01, 0.1 or 1 LM), renin release
rate did not change significantly. Isoproterenol (5 ) increased renin
release rate from 0.92 0.28 to 1.50 0.46 ng Al. hC' . Ar'/hr(N =
7, P < 0.01). After pretreatment of afferent arterioles with a-hANP (1
1.LM), isoproterenol still increased renin release rate from 0.98 0.24 to
1.64 0.37 ng A! . hr' . Af1/hr(N = 7, P < 0.01). The increases in
renin release rate induced by isoproterenol were not different between
the two groups. Pretreatment of rabbits with furosemide for two days
before experiments resulted in greater basal renin release rates from
microdissected afferent arterioles (1.70 0.35 ng Al. hr' .Af '/hr, N
= 14). However, exposure to a-hANP (1 tLM) did not alter this elevated
renin release rate. It is concluded that atrial natriuretic factor may not
have a direct action on juxtaglomerular cells.
Although effects of atrial natriuretic factor (ANF) on sys-
temic and renal hemodynamics have been studied extensively
[1, 2], reports on its action on renin release are scarce and
conflicting. Some in vivo studies [3—91 have reported that ANF
reduced renin release markedly especially when basal renin
release rates were high, whereas others [10, 11] have reported
no effect of this peptide on renin release. Since ANF has
marked renal hemodynamic actions, components affecting the
renin response to ANF are multiple in vivo. On one hand, an
enhanced delivery of sodium chloride to the macula densa
generated by ANF-induced increase in glomerular filtration rate
would be expected to decrease renin release rate according to
the macula densa hypothesis [12]. On the other hand, a de-
crease in blood pressure induced by an administration of ANF
may be expected to increase renin release rate [121. Thus, a
renin response to ANF could be a result of complex combina-
tion of changes such as these.
Using renal cortical slices, investigators [9, 13] reported that
synthetic ANF reduced both basal and acutely—stimulated renin
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release. Although this preparation is free from systemic hemo-
dynamic influences, it contains components other than afferent
arterioles which may affect renin response to ANF.
We have previously shown that the microdissected afferent
arteriole is a suitable model to study renin release in the
absence of glomeruli, tubules and macula densa [14]. Using this
preparation in the present study, we examined whether or not
ANF has direct actions on juxtaglomerular cells. We have used
a synthetic ANF, a-human atrial natriuretic polypeptide (a-
hANP), which is reported to mimic the action of the native
peptides [15—20]. First, we have examined whether a-hANP
alters basal renin release, second whether the pretreatment of
arterioles with a-hANP affects an acute renin response to
isoproterenol, and finally whether a-hANP alters elevated basal
renin release from afferent arterioles obtained from rabbits
pretreated with intramuscular injections of furosemide.
Methods
The following materials were obtained commercially: Eagle
minimal essential medium (MEM) from Nissui Pharmaceutical
Co. (Tokyo, Japan); sodium heparin, from Novo Industries
(Demmark); sodium pentobarbital from Abbott Laboratories
(North Chicago, Illinois, USA); bovine serum albumin (BSA)
and L-ascorbic acid from Wako Pure Chemical Industries
L.T.D. (Osaka, Japan); isoproterenol from Sigma Chemical Co.
(St. Louis, Missouri, USA); synthetic a-human atrial natri-
uretic polypeptide of 28 amino acids (a-hANP) from Protein
Research Foundation (Osaka, Japan). Furosemide was from
Hoechst Japan Limited (Tokyo, Japan).
Isolation of afferent arterioles and incubation procedure
The methods for the isolation and incubation of afferent
arterioles were similar to those previously decribed [14].
Briefly, young Japanese white rabbits (2.0 to 3.0 kg) maintained
on standard rabbit chow and tap water ad libitum were anes-
thetized with sodium pentobarbital (40 mg/kg, i.v.) and given an
intravenous injection of heparin (1,000 U). The left kidney was
perfused in situ with cold, oxygenated (95% 02 and 5% C02)
MEM containing 0.1% BSA (MEM-0. l%BSA). The kidney was
then removed and sliced along the corticomedullary axis. Slices
were placed in ice—cold MEM and microdissected at 4°C under
a stereomicroscope at a magnification up to X 100. Twenty to 30
afferent arterioles were microdissected from the superficial
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Table 1. Eifect of a-hANP on basal renin release
Group N
Renin release rate
ng Al hr1 Ar Vhr
.Arteriolar renin
content ngAl hr/MI II
Control 6 0.80 0.24 0.88 0.18 24.3 6.29
a-hANP
1.0 x 106M 6 0.69 0.15 0.85 0.20 31.4 7.32
1.0 x l07M 6 1.13 0.38 1.43 0.37 36.1 7.55
1.0 x l08M 6 1.03 0.34 1.23 0.33 33.4 5.88
Values are mean SCM, N refers to the number of experiments.
cortex in 90 minutes and divided into control and experimental
groups of approximately five afferent arterioles each.
Microdissected arterioles in each group were transferred into
a small plastic ladle that had a nylon mesh (45 m; Tetko, Inc.,
Elmsford, New York, USA) bottom. The ladles with afferent
arterioles were preincubated in 1 ml of oxygenated MEM-
0. 1%BSA for 35 minutes. After preincubation, each ladle was
rinsed, blotted and transferred into a small plastic microtube
containing 100 1.d of oxygenated MEM-0. l%BSA. The gas layer
above the incubation medium was replaced with 95% 02 + 5%
C02, and the microtubes were covered tightly. The microdis-
sected afferent arterioles were incubated for 20 minutes and
then the ladle was transferred to fresh medium for another
20-minute incubation period. Incubation medium left in the
microtube was frozen (—25°C) until the renin assay was per-
formed. After serial incubations were completed, it was con-
firmed microscopically that all arterioles remained in the ladle.
Arterioles were then placed in 100 d of distilled water and
frozen immediately. After the tissue samples were thawed, 900
d of MEM-0. 1%BSA was added to bring the total volume to 1
ml. These tissue samples were stored frozen until the renin
assay was performed.
Experimental protocol
Time control. Afferent arterioles were incubated in MEM-
0. 1%BSA for two 20-minute periods concurrently with each of
the experimental groups.
a-hA NP. Afferent arterioles were incubated in MEM-
0. 1%BSA for the first (control) period and then placed in
medium containing a-hANP for the second (experimental)
period. Three concentrations of a-hANP were tested: 1.0 X
106, 1.0 X l0-, and 1.0 X 108M.
a-hANP was dissolved in distilled water at the concentration
of 1.0 x 104M and stored frozen at —80°C. Biological activity
of stock solution was examined in vivo. An intravenous admin-
istration of 0.43 g a-hANP in bolus doubled urine, flow rate in
anesthetized rats, showing that stock solution was biologically
active. It was also confirmed that diuretic and natriuretic
actions of a-hANP were not attenuated after incubation with
afferent arterioles.
Isoproterenol. Before examining the effect of a-hANP on
acute renin response to isoproterenol, a dose—response relation-
ship for changes in renin release rates induced by isoproterenol
was determined. Afferent arterioles were exposed to isoproter-
enol during the experimental period. Three concentrations of
isoproterenol were tested: 1.0 x iO, 1.0 x 106, and 1.0 x
Table 2. Effect of isoproterenol on renin release
Group N
Renin rele
ng A! hrase rateAr '/hr
.Arteriolar renin
content ngAl hr/AfI II
Control 6 1.06 0.25 1.10 0.34 32.5 11,9
Isoproterenol
1.0 x l04M 6 0.94 0.29 2.38 0.30a 36.7 12.5
1.0 x 106M 6 0.95 0.49 1.54 0.61° 49.7 15.1
1.0 x 108M 6 1.13 0.46 1.27 0.38 24.6 4.47
Values are mean SEM, N refers to the number of experiments.
a P < 0.01 compared with control period (I).
108M. In this experiment, incubation medium contained 0.1%
L-ascorbic acid to prevent degradation of isoproterenol.
Pretreatment of afferent arterioles with a-hANP. Afferent
arterioles were pretreated with a-hANP (1.0 x 106M). a-hANP
was present from the preincubation to the end of incubations,
and isoproterenol at 5.0 x l06M was added to the incubation
medium for the second incubation period. The incubation
medium contained 0.1% L-ascorbic acid for the same reason as
above.
Enhancing basal renin release rate. In an attempt to examine
the effect of a-hANP on the enhanced basal renin release from
isolated afferent arterioles, rabbits were pretreated with intra-
muscular injections of furosemide (20 mg, twice a day) for two
days. The last injection of furosemide was done sixteen hours
before the experiment. With this pretreatment, rabbits lost 7.15
0.62% (N 5) of the initial body weight. Microdissection and
incubation were performed as described and a-hANP (1.0 x
106M) was added to the incubation medium for the second
incubation period.
Analysis of renin activity
Incubation medium and tissue samples were incubated with
partially—purified rabbit substrate equivalent to 600 ng Al at
37°C for three hours (PH, 6.5). Generated Al was measured by
radioimmunoassay. Substrate was prepared by ammonium sul-
fate fractionation of the plasma obtained from 48-hour nephrec-
tomized rabbits. Substrate had specific activity of 500 ng AT/mg
protein and had no detectable renin or angiotensinase activity.
Renin release rate was calculated as nanogram of Al gener-
ated per hour per arteriole (At) per hour incubation of arteriole
and expressed as ng AT. hr' .Af' '/hr. Tissue renin content of a
single arteriole was calculated and expressed as ng AT. hr 'IM.
All data were expressed as mean SEM. Student's paired and
unpaired t-tests were used for the statistical evaluation. A
P-value of less than 0.05 was considered to be significant.
Results
Time control
All data from each time control experiment were combined
together. Renin release rate during the first and second incuba-
tion periods were 0.97 0.13 and 0.95 0.14 ng
AT hr"' . ArVhr (N = 18), respectively, showing that it was
stable throughout the incubation periods. Renin release rate
during the first incubation period was 3.8 0.7 1% of arteriolar
renin content per hour which is similar to that reported previ-
ously [14, 21].
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Group N
Renin release rate
ng A! hr Af 1/hr
.Artertolar renin
content ngA! hr'/AfI II
Non-pretreated
Time control 6 1.05 0.22 0.87 0.23 76.4 18.4
Isoproterenol




Time control 6 1.34 0.15 1.46 0.21a 107.6 25.6
Isoproterenol
5.0 x lO5M 7 0.98 0.24 1.64 0.37a 73.5 16.1
a-hA NP
As shown in Table 1, exposure of afferent arterioles to
a-hANP altered neither basal renin release rate nor arteriolar
renin content.
Isoproterenol
Table 2 shows the effect of isoproterenol on renin release
from afferent arterioles. When arterioles were exposed to
isoproterenol at 1.0 x 104M, renin release rate increased
significantly (P < 0.01) from 0.94 0.29 to 2.38 0.30 ngAl. hr . Ar'/hr. Exposure to isoproterenol at 1.0 x 106M
also increased renin release rate from 0.95 0.49 to 1.54 0.61
ng Al . hr' . Af/hr (P < 0.05). Increase in renin release rate
during exposure to 1.0 x 104M isoproterenol was 1.44 0.24
ng Al . hr . Af1/hr, which was significantly (P <0.01) larger
than that during exposure to 1.0 x 106M isoproterenol (0.6
0.15 ng Al . hc' . ArVhr). However, exposure to 1.0 x 108M
isoproterenol did not result in a significant change in renin
release rate.
Pretreatment of arterioles with a-hA NP
Table 3 and Figure 1 show the effect of the pretreatment of
afferent arterioles with a-hANP on isoproterenol—induced renin
release. Basal renin release rate during the control (first incu-
bation) period was 1.15 0.15 ng Al . hr' . ArVhr (N = 13)
in a-hANP-pretreated group, which was not different than that
of non-pretreated group (0.98 0.17 ng Al. hr . Af'/hr,
N= 13). Isoproterenol at 5.0 x l06M increased renin release
rate from 0.98 0.24 to 1.64 0.37 ng Al . hr1 . Af'/hr in
a-hANP-pretreated group (P < 0.01) and from 0.92 0.28 to
1.50 0.46 ng Al. hr . AfVhr in non-pretreated group (P <
0.05). The increases in renin release rate during exposure to
isoproterenol were not different between the two groups (Fig. 1;
0.65 0.19 and 0.59 0.18 ng Al. hr' . Afhr in a-hANP-
pretreated and non-pretreated groups, respectively).
Enhancing basal renin release rate
When arterioles were obtained from rabbits pretreated with
furosemide for two days, renin release rates during the first and
second incubation periods were 1.70 0.35 and 1.91 0.39 ng
Al . hr . Af/hr, respectively (Table 4). While the pretreat-
Fig. 1. Effect of the pretreatment with a-hANP on basal and isopro-
terenol—induced renin release. a-hANP at 1.0 x 106M was present
from preincubation to the end of incubations (closed circle and square).
Afferent arterioles were exposed to isoproterenol (Iso) at 5.0 x 106M
during the second incubation period (sequare symbols). < 0.01
compared with control group. < 0.01 compared with a-hANP (time
control) group.
Table 4. Fifect of a-hANP on enhanced basaI renin release
Group N
Renin release rate
ng Al hr . Af/hr .Arteriolar renin
content ngAl hr'/AfI H
Non-pretreated
Control 18 0.97 0.13 0.95 0.14 44.4 9.04
Pretreated with
furosemide
Control 14 1.70 0.35a 1.91 Ø39a 60.8 10.2
a-hANP 10 1.95 0.33 2.25 0.30 120.5 38.0
1.0 x 106M
ment with furosemide did not affect arteriolar renin content, it
increased basal renin release rates significantly. Even when
afferent arterioles have elevated basal rates of renin release,
a-hANP altered neither renin release rate nor arteriolar renin
content (Table 4).
Discussion
We have previously shown that microdissected afferent arte-
riole is a viable and suitable preparation for the study of renin
release [14, 211. This preparation allows us to study renin
release in the absence of glomeruli, tubules and macula densa
that may affect renin responses to various substances. Using
this preparation, the present study was undertaken to examine
the direct effect on renin release of synthetic a-hANP which is
shown to mimic biological actions of authentic natural peptides
[19]. The results suggest that ANF does not have a direct action
on renin release from juxtaglomerular cells.















Values are mean SEM, N refers to the number of experiments.
a p < 0.01 compared with control period (I).
Control Experimental
Incubation period
Values are mean SEM. N refers to the number of experiments.
a P < 0.025 compared with non-pretreated group.
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In vivo, ANF decreases renin release markedly and revers-
ibly [3—7]. In addition to inhibiting renin release, ANF increases
glomerular filtration rate [1, 2], which would lead to enhanced
sodium chloride delivery to the macula densa region of the thick
ascending limb of the loop of Henle. Previous studies have
established an inverse relationship between sodium chloride
load to the macula densa and renin release rate [12], which is
known as the macula densa mechanism of renin release, There-
fore, it was reasonably speculated that ANF could decrease
renin release by the macula densa mechanism and/or by a direct
action on juxtaglomerular cells [3—5]. In the present study,
however, a-hANP altered neither basal nor isoproterenol—
stimulated renin release from microdissected afferent arterioles.
These results are consistent with those reported by Opgenorth
et al [22] that renin release rates were not altered by intrarenal
infusion of synthetic ANF in the nonfiltering kidney. The
findings of the present study and those of Opgenorth et al
suggest that ANF has no direct action on juxtaglomerular cells
and that decrease in renin release seen in previous in vivo
studies is secondary to systemic changes induced by the admin-
istration of ANF.
In contrast to the present observations, Obana et al [9] and
Henrich et al [13] report that synthetic rat ANF decreased both
basal and isoproterenol stimulated renin release in rat renal
cortical slices, suggesting that ANF has a direct inhibitory
action on renin release from juxtaglomerular cells. The reason
for the discrepancy between the present observations and those
of Obana et a! and Henrich et al is presently unclear, but may be
due to the difference in the species (rat versus rabbit) or in the
experimental preparations (isolated afferent arterioles versus
renal cortical slices).
It may be argued that since basal renin release rate is small in
our preparation, a decrease in renin release may have not been
detected even if a-hANP actually decreased renin release rate.
However, we have previously shown that adenosine can de-
crease renin release in our preparation [23].
There are reports that both do [3—9] and do not [10, 11]
support an inhibitory action of ANF on renin release, and it has
been speculated that this discrepancy may be related to the
basal rate of renin release. Maack et a! [3] and Burnet, Granger
and Opegnorth [4] reported that intravenous or intrarenal
administration of synthetic ANF markedly decreased renin
release in normal anesthetized dogs. In conscious rats with two
kidney—one clip or salt—depleted one kidney—one clip Goldblatt
hypertension, ANF was shown to decrease renin release [6, 81.
Similarly, in conscious dog with inferior vena cava ligation,
ANF markedly suppressed renin release rate [5]. ANF, how-
ever, failed to alter renin release in normal conscious dogs [51
and in conscious rats with normal or salt—repleted one kidney—
one clip Goldblatt hypertension [6]. Thus, it has been suggested
that ANF may inhibit renin release under the conditions where
baseline release rates are high, including anesthesia, renin
dependent hypertension and inferior vena cava construction. In
the present study, however, a-hANP had no effect on renin
release from microdissected afferent arterioles even though
basal release rate was elevated by the pretreatment of rabbits
with furosemide. This suggests that an inhibitory action of ANF
on renin release is not directly related to the high basal release
rates. ANF may decrease ream release in vivo, rather, by the
mechanisms other than direct action on juxtaglomerular cells,
probably by the macula densa mechanism which is thought to
be activated in renin dependent hypertensive models.
In conclusion, the results of the present study provide
evidence that ANF has no direct action on juxtaglomerular
cells. They suggest that the reported suppression of renin
release by ANF is due to an indirect mechanism, probably due
to the ANF-induced increase in glomerular filtration rate and,
therefore, increase in sodium chloride load to the macula densa.
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